Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2022-11, Vol.24 (11), p.2273-2276
Hauptverfasser:	Snitker, Søren, Egebjerg, Christina, Frederiksen, Marie, Sparre, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics antiobesity drug Body weight clinical trial Diabetes Diabetes Mellitus, Type 2 - drug therapy Drug administration Drug therapy GLP‐1 analogue Glucagon-Like Peptides - therapeutic use Humans Hypoglycemic Agents Injections Obesity Obesity - complications Obesity - drug therapy obesity therapy Overweight Overweight - complications Overweight - drug therapy Patient satisfaction phase III study Research Letter Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!